In this episode, we dive into GOG‑3101 TroFuse‑20—a Phase 3, randomized, active‑controlled, open‑label, multicenter study evaluating MK‑2870 monotherapy versus Treatment of Physician’s Choice as second‑ or third‑line therapy for patients with recurrent or metastatic cervical cancer.